Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 267,933 shares of the biotechnology company's stock after selling 2,939 shares during the quarter. Rhumbline Advisers owned about 0.28% of Sarepta Therapeutics worth $32,578,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in SRPT. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $79,425,000. Janus Henderson Group PLC raised its position in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after buying an additional 543,143 shares during the last quarter. Soros Fund Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth $25,800,000. Finally, Swedbank AB purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $16,706,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $2.13 during trading on Friday, reaching $106.28. The company had a trading volume of 709,165 shares, compared to its average volume of 811,166. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $101.15 and a twelve month high of $173.25. The stock has a 50-day moving average price of $117.88 and a two-hundred day moving average price of $123.85. The stock has a market capitalization of $10.15 billion, a PE ratio of 85.02 and a beta of 0.75.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SRPT shares. HC Wainwright reissued a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 13th. Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Evercore ISI dropped their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a "hold" rating and a $136.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $176.77.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.